SCHEMBL6799228

SCHEMBL6799228

Cc1nc(CCN(C(=O)O)c2ccc(NC(=O)c3ccccc3-c3ccc(Cl)cc3)cc2)cs1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 5/20 0.47
NPC1 O15118 4/20 0.47
KDM4E B2RXH2 3/20 0.47
STAT1 P42224 2/20 0.47
MAPT P10636 5/20 0.46
SMN1; SMN2 Q16637 4/20 0.46
NFKB1 P19838 2/20 0.44
NFKB2 Q00653 2/20 0.44
RELA Q04206 2/20 0.44
ALDH1A1 P00352 4/20 0.41
GAA P10253 2/20 0.41
KMT2A Q03164 4/20 0.41
SMO Q99835 3/20 0.41
MEN1 O00255 3/20 0.41
HPGD P15428 2/20 0.41
CYP1A2 P05177 1/20 0.41
CYP2C19 P33261 1/20 0.41
NPSR1 Q6W5P4 2/20 0.40
L3MBTL1 Q9Y468 2/20 0.40
NPY1R P25929 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6502807 0.91 GCGR (0.48) RAB9ANPC1KDM4ESTAT1MAPT
SCHEMBL6492959 0.90 F10 (0.42) RAB9ANPC1KDM4ESTAT1MAPT
SCHEMBL6789318 0.84 NPC1 (0.52) RAB9ANPC1KDM4ESTAT1MAPT
SCHEMBL6794094 0.80 CCR2 (0.39) RAB9ANPC1MAPTALDH1A1GAA
SCHEMBL6499324 0.80 POLB (0.41) RAB9ANPC1KDM4EMAPTSMN1; SMN2
SCHEMBL6794499 0.80 CYP3A4 (0.40) RAB9ANPC1KDM4ESTAT1MAPT
SCHEMBL6791537 0.80 GAA (0.48) RAB9ANPC1KDM4ESTAT1MAPT
SCHEMBL6491047 0.79 APOB (0.44) RAB9ANPC1KDM4ESTAT1MAPT
SCHEMBL6792786 0.79 KMT2A (0.44) RAB9ANPC1KDM4ESTAT1MAPT
SCHEMBL6798629 0.78 KMT2A (0.37) RAB9ANPC1KDM4ESTAT1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040058903-A1 Benzamide compounds as apo b secretion inhibitors FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2004-03-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040058903-A1 Benzamide compounds as apo b secretion inhibitors APOB, APOL1, SCARB1 RAB9A 3707/4885NPC1 64/4885KDM4E 3114/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.